Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 5, 2012, Pages 265-277

  Nirogi, Ramakrishna ^a   Bhyrapuneni, Gopinadh ^a,b   Kandikere, Vishwottam ^a   Muddana, Nageswararao ^a   Saralaya, Ramanatha ^a   Komarneni, Prashanth ^a   Mudigonda, Koteshwara ^a   Mukkanti, K ^b  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

amniotic fluid; antiretroviral fixed dose combination; fetal tissue; placental tissue; timed pregnant rat pharmacokinetics

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

AMNION FLUID; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SCREENING; FEMALE; FETUS (ANATOMY); HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PLACENTA; PLACENTAL TRANSFER; PREGNANCY; PRENATAL DRUG EXPOSURE; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY;

ADENINE; ADMINISTRATION, ORAL; AMNIOTIC FLUID; ANIMALS; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FETUS; HIV INFECTIONS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; ORGANOPHOSPHONATES; OXAZINES; PLACENTA; PREGNANCY; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84863723468     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1794     Document Type: Article

References (48)

1. Joint United Nations Programme on HIV/AIDS 'Overview of the global AIDS epidemic. 2006. Report on the global AIDS epidemic'. Retrieved on 2006-06-08.
2. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Department of HIV/AIDS, Department of Reproductive, Health and Research, World Health Organization: Geneva, 2004.
3. Tovo PA, Newell ML, Mandelbrot L, Semprini A, Giaquinto C,. Recommendations for the management of HIV infected women and their infants-A European Consensus. European Commission: Luxembourg, 1999; 1-37.
4. Mandelbrot L, LeChenadec J, Berrebi A,. Perinatal HIV-1 transmission-interaction between zidovudine prophylaxis and mode of delivery in the French perinatal cohort. JAMA 1998; 280: 55-60. (Pubitemid 28414997)
5. Kind C, Rudin C, Siegrist CA,. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205-210. (Pubitemid 28035162)
6. Lorenzi P, Spicher VM, Laubereau B,. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12: F241-F247. (Pubitemid 28558591)
7. Blattner W, Cooper E, Charurat M,. Effectiveness of potent antiretroviral therapies on reducing perinatal transmission of HIV-1. Presented at XIII International AIDS Conference, Durban, South Africa, July 9-14, 2000 [abstract LbOr4].
8. Thorne C, For the European Collaborative Study. Antiretroviral therapy and caesarean section to reduce vertical transmission of HIV in Europe. Presented at XIII International AIDS Conference, Durban, South Africa, July 9-14, 2000 [abstract MoOrC240].
9. David W, Jason B, Zelalem T,. Antiretroviral drugs. J Clin Pharmacol 2007; 47: 1570-1579.
10. Ledergerber B, Egger M, Opravil M, et al,. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863.
11. Mocroft A, Ruiz L, Reiss P, et al,. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17: 1741.
12. Nirogi R, Bhyrapuneni G, Kandikere V, et al,. Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. Biomed Chromatogr 2009; 23: 371-381.
13. Frampton JE, Croom KF,. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs 2006; 66: 1501.
14. Gedeon C, Koren G,. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 2006; 27: 861-868. (Pubitemid 43905924)
15. Blum MR, Chittick GE, Begley JA, et al,. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol 2007; 47: 751-759. (Pubitemid 46800418)
16. Ramanathan G, Shen G, Cheng A, et al,. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007; 45: 274-279. (Pubitemid 47012373)
17. Cao J, Huang L, Liu Y, et al,. Differential regulation of hepatic bile salt and organic anion transporters in pregnant and postpartum rats and the role of prolactin. Hepatology 2001; 33: 140-147. (Pubitemid 32016896)
18. Keppler D, Konig J,. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 1997; 11: 509-516. (Pubitemid 27274424)
19. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D,. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994; 54: 4833-4836. (Pubitemid 24289409)
20. Suzuki H, Sugiyama Y,. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin Liver Dis 1998; 18: 359-376. (Pubitemid 29011040)
21. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D,. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996; 56: 988-994. (Pubitemid 26065391)
22. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE,. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35: 340-344. (Pubitemid 46333919)
23. Van Rompay KKA, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T,. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52: 3144-3160.
24. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM,. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: Is it time to move on from zidovudine. HIV Med 2009; 10: 397-406.
25. European Medicines Agency. Atripla 600mg/200 mg/245mg film-coated tablets: summary of product characteristics [online]. Available from URL: [Accessed 2010 Oct 13].
26. European Medicines Agency. Viread 245 mg film-coated tablets: summary of product characteristics [online]. Available from URL. [Accessed 2010 Sep 28].
27. Deeks ED, Perry CM,. Efavirnez/emitricitabine/tenofovir disoproxil fumarate single tablet regimen (Atripla). Drugs 2010; 70: 2315-2338.
28. Clark TN, White CA, Chu CK, Bartlett MG,. Determination of 3-azido-2,3-dideoxyuridine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography. J Chromatogr B 2001; 755: 165-172. (Pubitemid 32324082)
29. Beachy JC, Weisman LE,. Acute asphyxia affects neutrophil number and function in the rat. Crit Care Med 1993; 21: 1929-1934. (Pubitemid 23349898)
30. Dawson BV, Johnson PD, Goldberg SJ, Ulreich JB,. Cardiac teratogenesis of trichloroethylene and dichloroethylene in a mammalian model. J Am Coll Cardiol 1990; 16: 1304-1309. (Pubitemid 20378487)
31. Fujinaga MJ, Baden M, Suto A, Myatt JK, Mazze RI,. Preventative effects of phenoxybenzamine on nitrous oxide-induced reproductive toxicity in Sprague-Dawley rats. Teratology 1991; 43: 151-157.
32. Huang S, Remmel HRP, Zimmerman CL,. The bioavailability and nonlinear clearance of (-)-carbovir in the rat. Pharm Res 1991; 8: 739-743.
33. Huang C, Boudinot FD, Feldman S,. Maternal-fetal pharmacokinetics of zidovudine in rats. J Pharm Sci 1996; 85: 965-970. (Pubitemid 26300225)
34. Boike GM, Deppe G, Young JD, Malone JM, Malviya VK, Sokol RJ,. Chemotherapy in a pregnant rat model. 2. 5-Fluorouracil: nonlinear kinetics and placental transfer. Gynecol Oncol 1989; 34: 191-194. (Pubitemid 19191075)
35. Faber JJ, Thornburg KL,. Placental Physiology: Structure and Function of Fetomaternal Exchange. Raven: New York, 1983.
36. Hirt D, Urien S, Ekouevi DK, et al,. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 2009; 85: 182-189.
37. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB,. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29: 207-220. (Pubitemid 34208529)
38. Macfarland A, Abramovich DR, Ewen SW, Pearson CK,. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 1994; 26: 417-423. (Pubitemid 24171685)
39. Hutson JR, Koren G, Matthews SG,. Placental P-glycoprotein and breast cancer resistance protein: Influence of polymorphisms on fetal drug exposure and physiology. Placenta 2010; 31: 351-357.
40. Meyer ZU, Schwabedissen HE, Jedlitschky G, et al,. Variable expression of MRP2 (ABCC2) in human placenta: Influence of gestational age and cellular differentiation. Drug Metab Dispos 2005; 33: 896-904. (Pubitemid 41002769)
41. St-Pierre MV, Serrano MA, Macias RI, et al,. Expression of members of multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1495-R1503.
42. Ray AS, Cihlar T, Robinson KL, et al,. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-3304. (Pubitemid 44527501)
43. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y,. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007; 71: 619-627. (Pubitemid 46147926)
44. Leazer TM, Klaassen CD,. The presence of xenobiotics transporters in rat placenta. Drug Metab Dispos 2003; 31: 153-167. (Pubitemid 36159607)
45. Azzaroli F, Mennone A, Feletti V, et al,. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment Pharmacol Ther 2007; 26: 1139-1146. (Pubitemid 47480961)
46. Chen C, Klaassen CD,. Rat multidrug resistance protein 4 (Mrp4, Abcc4): molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. Biochem Biophys Res Commun 2004; 317: 46-53. (Pubitemid 38401963)
47. Zhou F, You G,. Molecular insights into the structure-function relationship of organic anion transporters OATs. Pharm Res 2007; 24: 28-36. (Pubitemid 44902567)
48. Anzai N, Kanai Y, Endou H,. Organic anion transporter family: current knowledge. J Pharmacol Sci 2006; 100: 411-426. (Pubitemid 44609532)